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Abstract  
 
Background: Little is known about pregnancy patterns and levels of HIV RNA in HIV-infected women 
conceiving on highly-active antiretroviral therapy (HAART) with non-suppressed viral load (VL), nor their 
therapeutic management.  
 
Methods: Linear mixed models were fitted to study changes in VL and potential associated factors 
including HAART type/duration and immune status among 127 women receiving HAART at conception 
with detectable VL enrolled in the prospective European Collaborative Study. 
 
Results: Median duration of HAART at conception was 10 months. Seventy-eight (61%) women 
conceived on PI-based HAART. Seventy-two (57%) women remained on the same HAART regimen 
throughout pregnancy, 24 (19%) switched regimens and 31 (24%) interrupted HAART during early 
pregnancy. The intention-to-treat model indicated constant VL up to 10 gestational weeks; thereafter 
levels decreased significantly, by 0.06 log10 copies/ml weekly until delivery. At baseline, immune status 
was significantly associated with HIV RNA levels. Excluding treatment-interrupters, there was no 
significant difference in VL slope between women who did and did not modify their HAART regimens 
(p=0.14); women conceiving on NNRTI-based HAART had consistently lower VL throughout pregnancy 
than those on PI-based HAART (p=0.02). Most (64/103, 62%) women had detectable VL within four 
weeks of delivery (median 2.40 log10 copies/ml). The MTCT rate overall was 1.72% (95%CI 0.21-6.1%). 
 
Conclusion: Practices regarding management of women conceiving on HAART with detectable VL vary 
in Western Europe. The existence of this group of pregnant women highlights the need for improved 
monitoring of and support for treated women before they become pregnant, as well as during pregnancy 
itself. 
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Introduction 
 
In developed countries, widespread use of highly-active antiretroviral therapy (HAART) has resulted in 
decreases in HIV-related morbidity and mortality [1-3] and mother-to-child transmission (MTCT) rates [4-
7]. Consequently, increasing numbers of HIV-infected women are becoming pregnant or planning 
pregnancies [8, 9], with many on HAART at conception [6, 10]; in the UK and Ireland, 24% of HIV-infected 
women on HAART delivering in 2000-2006 conceived on HAART, around 40% of the total diagnosed with 
HIV infection before pregnancy [6]. Of women conceiving on HAART, those with detectable HIV RNA 
levels at their first antenatal visit are of particular interest as control of viral replication is key to reducing 
MTCT risk [4,11,12] and preventing disease progression [13,14]. In terms of MTCT risk, viral load during 
the later stages of pregnancy are of most importance; we have previously shown that NNRTI-based 
HAART initiated in pregnancy in treatment-naive women was associated with more rapid VL decline than 
PI-based HAART [15]. Little is known about  treatment or likelihood, or timing, of achieving undetectable 
viral load (VL) in women who conceive while on HAART with detectable VL. In particular, no studies to 
date have been carried out to describe the virological patterns in pregnancy in this group of women.  
 
Using data from a European multicentre prospective cohort study, this analysis was conducted to assess 
the pattern and levels of HIV RNA in pregnancy in HIV-infected women on HAART with non-suppressed 
VL at conception taking into account treatment modifications and to identify factors which may affect these 
levels and patterns, including type of HAART and maternal factors.  
 
Methods 
 
The study population was selected from women enrolled in the European Collaborative Study (ECS), a 
prospective cohort study in which HIV-infected pregnant women were enrolled and followed in pregnancy, 
and their children followed from birth [15, 16]. Informed consent and ethical approval were obtained 
according to local guidelines. Maternal information routinely collected included socio-demographic 
characteristics, obstetrical history and HIV-specific information, including ART use, CD4 counts and 
plasma HIV RNA VL. HIV RNA quantification was performed using commercially available assays. 
Classification of undetectable viral load was based on the lower limit of quantification of the assay used.  
Amplicor HIV-1 Monitor Tests (Standard version 1.5 and ultrasensitive, Roche Diagnostic Systems Inc., 
Branchburg, NJ, USA) was used for most (73%) measurements, of which 97% were measured with the 
ultrasensitive assay with a quantification limit of <50 copies/ml.  
 
Overall, a total of 569 women conceived on HAART with date of HAART initiation reported: of these, 255 
had undetectable VL at conception and 180 did not have VL or CD4 counts available. Of the remaining 
134 women, we excluded seven women who conceived whilst taking HAART containing both a protease 
inhibitor (PI) and a non-nucleoside reverse transcriptase inhibitor (NNRTI). Our study population therefore 
comprised of 127 women on HAART at conception (i.e. receiving at least three drugs including either a PI 
or a NNRTI), with known initiation date, detectable VL at first antenatal visit and ≥1 CD4 count reported by 
June 2007. 
 
Statistical methods 
The pattern of log10 transformed HIV RNA VL over pregnancy was described using a supersmoother (an 
adaptive running mean in which the sampling window size varies according to local density of 
measurements). Linear mixed effects models were used to explore log10 HIV RNA VL over pregnancy; this 
approach allows inclusion of random effects and is appropriate for analysis of repeated measures data. 
Left-censoring patterns of VL due to undetectable measurements were dealt with using parametric 
censored regression [17, 18]. To account for between-woman variability in VL, we fitted individual random 
effects for VL at the time of the change point (model intercept) and the subsequent slope; this 
incorporated the association between the value of VL at the time of change-point and the slope which 
models changes in VL thereafter.  
 
Covariates considered in the models included time of VL measurement (gestational weeks), ethnic group 
stratified by history of injecting drug use (IDU) into white with IDU history, white without IDU history and 
black (as no black woman had an IDU history), type (PI-containing or NNRTI-containing) and duration of 
HAART, time period of delivery (to account for changes over time in HIV management), baseline CD4 
count and HIV RNA assay type (Roche or other) [19]. An intention-to-treat approach was taken for the first 
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model, which included all women (model 1). A two-phase linear mixed model best described the functional 
form of VL, with the change-point of the slope taken as 10 gestational weeks, the time at which the model 
Akaike Information Criteria (a goodness of fit criterion that allows comparison of non-nested models) was 
minimised. The model was then refitted, firstly excluding women who interrupted treatment (on the basis 
that this group were potentially at risk of viral rebound [13]) with adjustment for whether or not the HAART 
regimen at conception was modified later in pregnancy for the remainder (model 2). A third model was 
fitted for the sub-group continuing on the same regimen from conception to delivery (i.e. without 
interruption or modifications) (model 3). For the models excluding women who interrupted treatment, the 
VL decline was linear and therefore models fitted for this group required only one slope to describe the 
change in VL over pregnancy (See Figure 1a). Statistical analyses were performed with SAS software, 
version 9.1 (SAS Institute, Cary, NC, USA) and with R version 2.6.1 (R Foundation for Statistical 
Computing, Vienna, Austria) in a Windows environment.  
 
 
Results 
 
The characteristics of the 127 women are summarized in Table 1. Most women were on PI-containing 
regimens (mostly unboosted PIs) and had been on HAART for nearly a year before conception. Of the 49 
women conceiving on NNRTI-containing HAART, 40 were on nevirapine-based regimens and nine on 
efavirenz; most of those on PI-containing HAART received non-boosted PIs, mostly nelfinavir (n=35). Only 
one woman with a history of IDU was known to be an active user. All the black women were born in Africa. 
Women had a median of three antenatal VL measurements (IQR 2-3), with the first VL and CD4 count 
measured at a median of 12 gestational weeks (IQR 8-20); less than a quarter of all VL measurements 
were undetectable (Table 1) and overall, 36% (n=46) women achieved a VL <50 copies/ml at least once 
during pregnancy. Figure 1 shows a scatterplot of HIV RNA measurements, with a supersmoother to 
summarize the trend over pregnancy. 
Overall, 72 (57%) women remained on the same HAART regimen from conception and throughout 
pregnancy, 24 (19%) switched HAART regimens and 31 (24%) interrupted HAART during early pregnancy 
(Table 2). Among the 31 women who interrupted therapy, this lasted a median of 9 weeks (IQR 7-14); 
they re-started at a median of 17 gestational weeks (IQR 14-21), in 18 cases on the same regimen. The 
24 women who switched HAART regimens had higher HIV RNA levels at first antenatal measurement 
(p=0.07) and lower median CD4 count (p=0.019) than those who stayed on the same HAART regimen 
(Table 2). Of these 24 women, six switched from efavirenz (two to nevirapine and four to a PI) and three 
from nevirapine (all to a PI); of the 15 conceiving on PIs, 10 switched to another PI-containing regimen 
and five to nevirapine. There was no difference in HAART type at conception between the women who 
switched and those who continued regimens (χ2=0.06, p=0.49) (Table 2).  
 
The 31 VL measurements on four Asian women and nine women with missing information on ethnicity 
and IDU (Table 1) were excluded from the regression analyses. Median VL for these women was not 
significantly different to the remaining 114 women (median 3.00 [IQR 2.58-3.86] vs. median 2.76 [IQR 
2.00-3.50] log10 copies/ml; Wilcoxon test p=0.15).  
 
The initial mixed model for HIV RNA levels over pregnancy was an intention-to-treat analysis including all 
114 women. The inclusion of any interaction terms did not result in significant improvements in the model. 
VL in pregnancy was estimated to remain constant at the beginning of pregnancy with a minor increase of 
0.06 log10 copies/ml per week up to 10 gestational weeks, at which time the mean VL was estimated to be 
3.19 log10 copies/ml (Table 3). HIV RNA levels thereafter decreased significantly, by an estimated 0.06 
log10 copies/ml per week until delivery, an approximate 13% weekly decrease in HIV RNA copies/ml. In 
the 4 weeks up to delivery, 27 (29%) achieved VL <50 copies/ml and the median in the remainder was 
2.71 log10 copies/ml (IQR 2.32-3.24). Black non-IDU women had an estimated mean VL 0.28 log10 
copies/ml higher than white non-IDU women and white women with an IDU history had levels 0.31 log10 
copies/ml lower than white non-IDU (Table 3), but these differences did not reach statistical significance. 
Women with baseline CD4 counts <500 cells/mm3 had significantly higher antenatal HIV RNA levels than 
those without such immunosuppression.   
 
When the model was refitted, excluding the 28 women who interrupted HAART during pregnancy (model 
2), HIV RNA levels declined significantly from baseline by an estimated 0.05 log10 copies/ml per week 
 5 
(Table 4). There was no significant difference in the slopes of VL between women who did and did not 
undergo modification to their HAART regimens, although women who were receiving NNRTI-based 
HAART at conception had consistently lower estimated HIV RNA levels than those on PI-based HAART. 
In the model excluding women who interrupted or modified their HAART (model 3), the significant decline 
in HIV RNA levels was of the same magnitude as seen in model 2 (Table 4). In both models, CD4 count 
significantly predicted HIV RNA levels over pregnancy, but only severely immunosuppressed women (ie 
CD4 counts <200 cells/mm3) had significantly higher levels than women with CD4 counts ≥500 cells/mm3. 
In model 3, the ethnic group difference noted in model 1, with black women having higher estimated HIV 
RNA levels compared with white non-IDU women, was apparent and marginally significant. The HAART-
type effect on HIV RNA levels seen in model 2, that is lower levels associated with NNRTI versus PI, 
remained in model 3.  
 
Overall, 64 (62%) of 103 women with reported HIV RNA levels within four weeks up to delivery had 
detectable VL at this time, with a median of 2.40 log10 copies/ml (range 1.40-2.95). None of these 64 
women transmitted infection to their infants, although the exact binomial 95% confidence limit was 5.6%. 
Overall, the MTCT rate for the whole study population was 1.27% (2/116, 95%CI 0.21-6.1%). 
 
 
Discussion 
 
This analysis was based on a group of HIV-infected pregnant women on HAART at conception but with 
detectable VL. Most of our study population could be considered as having sub-optimal viral suppression 
[12], as nearly two-thirds had been on HAART for at least 6 months, theoretically sufficient time for 
achievement of viral suppression [20]; however, three-quarters had baseline VL below 3.93 log10 and 
could thus be classified as having partial control of HIV replication (complete suppression of VL is the aim 
for PMTCT). Although most women remained on their pre-pregnancy HAART regimens throughout 
pregnancy, a quarter interrupted treatment in early pregnancy and a further fifth changed their HAART 
regimens. Our initial ITT analysis indicated a constant VL for the first 10 weeks of pregnancy, with a 
subsequent significant decrease until delivery of around 13% per week. As the ITT model included women 
who switched or interrupted HAART, potentially resulting in improved virological control or virological 
rebound respectively [13,14], we ran further models excluding the HAART modification group and/or the 
interruption group, with estimated significant declines of between 7% and 15% log10 copies/ml per week. 
In all models, NNRTI-based HAART at conception was associated with significantly lower VL throughout 
pregnancy. 
 
Guidelines [12,21] recommend that HIV-infected women planning a pregnancy are offered pre-conception 
counselling, which provides the opportunity to switch from antiretroviral drugs that may be associated with 
toxicity [12,22] and to optimize treatment through adherence assessment/support and/or regimen 
modification in order to attain a stable, maximally suppressed VL prior to conception. However, a 
considerable proportion of pregnancies among HIV-infected women are unintended. European studies 
have indicated prevalences of unplanned pregnancy of  51% to 58% [10,23] and pre-conception 
counselling rates of only 25% among HIV-positive women [24]; in the USA, underuse of effective 
contraception has been documented among HIV-positive women [25] and 83% of pregnancies in a study 
of HIV-positive youth were unplanned [26]. It was not recorded whether the women in our study had 
planned their pregnancies, but it is likely that a substantial proportion were unintended, consistent with 
their detectable VL.  
We showed a significantly declining VL during pregnancy, both for women remaining on their conception 
regimens and for those switching HAART regimens. We have previously documented declining VL in 
untreated women from our study, which may in part be due to pregnancy-related haemodilution, which 
could also explain some of the VL decline seen here [19]. For the women remaining on the same HAART, 
the VL decline may be partly explained by improved adherence after awareness of the pregnancy, but this 
could not be verified as adherence data were unavailable. Three-quarters of pregnant women in the 
American PACTG 1025 study reported perfect adherence to HAART (no missed doses 4 days before all 
study visits), with those antiretroviral-naïve before the pregnancy more than twice as likely to be perfectly 
adherent compared with antiretroviral-experienced women [27]. Women in our study with existing 
adherence problems may have been motivated to improve adherence once aware of their pregnancy 
and/or may have received more intensive/effective adherence support from their care providers compared 
with that received before pregnancy [28-30].  
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For the fifth of women who switched HAART regimens, their HIV physicians may have determined the 
need for a switch through adherence assessment and resistance testing, in accordance with clinical 
guidelines which state that women on failing HAART should have their regimens changed to maximize the 
likelihood of achieving undetectable VL by delivery [12,13,21]. This group may also include women for 
whom the caring physician may have had more concerns regarding viremia control and 
immunosuppression, suggested by higher VL in women with lower CD4 counts. Of note, treatment 
modifications took place at a median of 21 weeks gestation, possibly due to delayed notification of 
pregnancy to a woman’s HIV physician and/or testing lag times. In the non-pregnant HIV-positive 
population, delays between detection of virological failure and switching to a new regimen are not 
uncommon, with a six month delay reported for a third of such patients in a recent UK national audit [31]. 
The lack of a significant difference between the switching and the continuing HAART groups in terms of 
HIV RNA slopes in model two was confirmed by the almost identical slope in the model which excluded 
the modifying HAART group (model three). The fact that treatment change did not occur until around half-
way through pregnancy may have contributed to this finding. Women undergoing treatment modifications 
had significantly lower baseline CD4 counts than those continuing with the same HAART regimen (on 
average over 100 cells/mm3 lower), most likely reflecting treatment guidelines and an example of 
confounding by indication [13,14]. Although we adjusted for baseline CD4 count in the model, we lacked 
data on drug resistance and could not investigate whether women switching treatment not only had poorer 
immune status, but also more resistance than those remaining on the same regimens. 
 
Two key factors predictive of HIV RNA levels in pregnancy were baseline CD4 count and type of HAART 
at conception. In the ITT model, women with CD4 counts <500 cells/mm3 had significantly higher VL than 
other women, although in subsequent models this lost significance for the women with moderate CD4 
counts (200-499 cells/mm3). Women conceiving on NNRTI-containing regimens had consistenly lower VL 
than those on PI-containing HAART. We previously showed among antiretroviral-naïve women that those 
initiating HAART with a NNRTI-based regimen reached an undetectable VL more rapidly than those 
starting with a PI-based regimen (mainly non-boosted) [15]. Several studies have indicated that very high 
adherence levels are required to maintain virological suppression on PI-containing regimens (above 90%), 
higher than those required for NNRTI-containing HAART [32-34]; this could help explain our finding here 
that women conceiving on PI-based HAART had significantly reduced slope of VL decline versus those on 
NNRTI-based HAART. A further potential explanation of the differences by HAART type could relate to 
pharmacokinetics: some studies have reported low concentrations of nelfinavir and other PIs in the third 
trimester [35-37], while studies on plasma nevirapine concentrations have generally shown no significant 
differences between pregnant and non-pregnant women [38].  
 
Treatment interruption in pregnancy is not recommended by current guidelines as it may result in viral 
rebound and subsequent increased risk of immune and/or clinical deterioration, in addition to an increased 
MTCT risk [12,21,39]. A recent study from Italy examining the impact of interruption of therapy during 
pregnancy, found that interruption in the first trimester was associated with a 10-fold increased risk of 
MTCT, after adjusting for maternal VL, type of therapy and other factors [39]. Most women who 
interrupted therapy in our study population did so in the earlier years of the study [data not shown] and it is 
likely that this practice is becoming increasingly rare, underscored by the recent Italian results. Switches 
away from efavirenz due to concerns regarding terato-embryogenic toxicity risk are often advocated for 
pregnant women [12] and were also seen here.  
 
Study limitations include the observational nature of the data and lack of information on adherence, drug 
resistance, HIV subtype and immunological and virological patterns before pregnancy. Our ability to 
explore potential reasons behind the similar VL declines in the women who switched treatment and in 
those who remained on their conception regimens was therefore constrained. A limitation of our analyses 
was the inability to adjust for baseline VL, as women had their first measurement at different gestational 
ages. However the statistical approach used was able to account for the variability in intercepts between 
women which should reduce some of the bias from not adjusting for the baseline VL implicitly. However 
we modelled appropriately the left-censored HIV RNA measurements and avoided imputation with 
midpoints, which can result in biased parameter estimates and their standard errors [18]. An additional 
limitation was a relative overestimation of the effects of drugs that were used in HAART regimens in 
pregnant women during earlier years (e.g. nelfinavir), which have been largely substituted by more potent 
PIs today. Although antiretroviral-experienced, our study population had not yet accumulated long 
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durations of treatment and most had partial control of viremia and thus the generalizability of our findings, 
for example, to highly treatment experienced pregnant women with high VL at conception, remains 
uncertain. 
 
Our findings come from a “real life” setting, and indicate a variety of practices regarding the management 
of women conceiving on HAART with detectable VL in this Western European setting. The existence of 
this group of pregnant women highlights the need for improved monitoring of and support for treated 
women before they become pregnant, as well as during pregnancy itself. Clinical concerns during 
pregnancy include attempts at improving virological control to avoid MTCT and improve maternal health, 
whilst minimizing potential adverse effects on the fetus and mother, including the risk of exposure to 
potentially teratogenic drugs. The MTCT rate in our study population was just over 1%; concern regarding 
the risk of pregnant women on failing HAART developing drug resistance, which could potentially be 
vertically transmitted [40,41] is a key factor behind recommendations for switching regimens as soon as 
virological failure is determined. However, there is a lack of consensus regarding when to change HAART 
for virological failure in non-pregnant adults [13]; few studies are aimed at evaluating optimal antiretroviral 
management during pregnancy for women on HAART at conception, while clinical trial data on efficacy of 
different HAART regimens in pregnancy are lacking. This context may partly explain the finding here that 
only a fifth of women underwent a treatment switch in pregnancy. Future controlled studies are needed to 
obtain information on mechanisms for VL decrease and on optimal clinical management of HAART in 
pregnant women, who are already on treatment at conception, particularly those with accumulated 
resistance. 
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Table 1. Characteristics of women receiving HAART at conception and the 
available measurements on these women during pregnancy. 
 
Women (n=127) 
 n (%)† 
Type of HAART regimen 
   PI-containing 
   NNRTI-containing 
 
78 (61) 
49 (39) 
Race by IDU status 
   Black non-IDU 
   White non-IDU 
   White IDU 
   Other  
 
37 (32) 
47 (41) 
31 (27) 
12 
Age at delivery (years) 
   Median (IQR) 
   18-25 
   26-34 
    ≥35 
   Unknown 
 
33 (30-37) 
10 (8) 
63 (53) 
46 (39) 
8 
Time period of delivery 
   1998-1999 
   2000-2001 
   2002-2003 
   2004-2006 
 
21 (16) 
49 (38) 
49 (38) 
8 (6) 
Duration of HAART at time of conception  
   Median months (IQR) 
   ≥ 15 months 
   6-15 months 
   < 6 months 
 
 
10 (5, 20) 
42 (33) 
41 (32) 
44 (35) 
Measurements (n=371) 
 n (%)† 
 
Median baseline VL* (log10 copies/ml) (IQR) 
 
3.22 (2.61-3.92) 
 12 
 
No. of undetectable measurements  
   Total  
   First trimester 
   Second trimester  
   Third trimester 
   Delivery  
 
      Median VL at delivery (log10 copies/ml) (IQR) 
      Median VL at delivery among detectable 
 
 
79/363 (22) 
1/74 (1) 
23/140 (16) 
36/100 (35) 
21/50 (42) 
 
2.45 (1.45-2.99) 
2.89 (2.57-3.48) 
HIV RNA assay 
   Roche 
   Other 
 
270 (73) 
107 (27) 
 
Median baseline* CD4 count (cells/mm3) (IQR) 
 
380 (288-517) 
† - unless other stated 
* at first pregnancy measurement 
   
Abbreviations: IQR, interquartile range; VL, VL; PI, protease inhibitor; NNRTI, non-
nucleoside reverse transcriptase inhibitor 
 
Table 2 Immunological and virological characteristics and HAART type, by treatment sub-group   
 
 HAART type at 
conception 
First antenatal 
HIV RNA 
Median (IQR) 
log10 copies/ml 
Timing of first 
antenatal 
measurement 
Median (IQR) 
Gest weeks 
Gestational age 
at interruption 
or switch  
Median (IQR) 
 
N (%) with 
undetectable HIV 
RNA levels in 4 
weeks up to 
delivery 
 PI-
based 
N (%) 
NNRTI-
based 
N (%) 
First 
antenatal 
CD4 count  
Median (IQR) 
cells/mm3 
    
 
No change to regimen   
n=72 
 
49 (68) 
 
23 (32) 
 
421  
(304-560) 
 
2.77  
(2.44-3.65) 
 
12 (8-22) 
 
 
N/A 
 
24/60 (40) 
 
Interruption of HAART 
n=31 
 
14 (45) 
 
17 (55) 
 
360 
(270-412) 
 
4.08 
(3.37-4.45) 
 
12 (9-16) 
 
 
7 weeks (5-8) 
 
 
10/24 (42) 
 
Switch to new regimen 
n=24 
 
15 (63) 
 
9 (38) 
 
306 
(208-447) 
 
3.12 
(2.91-3.48) 
 
10 (6-16) 
 
 
21 weeks (15-24) 
 
5/19 (26) 
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Table 3 
Adjusted coefficients of change for log10 HIV RNA levels from intention-
to-treat model (n=114, N=342) 
 
 Coefficient 
(95%CI) 
p 
   
Mean at 10 gestational weeks  3.19 (2.55, 3.83) <0.0001 
Initial slope (<10weeks) 0.06 (-0.0, 0.13) 0.07 
Slope to delivery (≥10 weeks) -0.06 (-0.08, -0.05) <0.0001 
Race by IDU   
 White non-IDU 0.00  
 Black non-IDU 0.28 (-0.08, 0.65) 0.12 
 White IDU -0.31 (-0.73, 0.11) 0.24 
Time period   
 1998-1999 0.00  
 2000-2001 -0.03 (-0.53, 0.47) 0.90 
 2002-2006 -0.26 (-0.74, 0.23) 0.23 
Type of HAART regimen at conception   
 PI-containing 0.00  
 NNRTI-containing -0.25 (-0.56, 0.056) 0.11 
Duration of HAART by conception   
 ≥ 15 months 0.00  
 6-15 months 0.17 (-0.21, 0.55) 0.37 
 < 6 months 0.12 (-0.23, 0.46) 0.51 
HIV RNA assay    
 Roche 0.30 (-0.02, 0.62) 0.07 
 Other  0.00  
Baseline CD4 count (cells/mm3)   
 ≥ 500 0.00  
 200-499 0.37 (0.02, 0.73) 0.04 
 <200 0.73 (0.25, 1.21) 0.003 
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Table 4 
Adjusted coefficients of change for log10 HIV RNA levels from model excluding 
women who interrupted HAART (Model 2) (n=86, N=249) and from model 
excluding women who interrupted or modified HAART (Model 3) (n=65, N=181)  
 
 Model 2 Model 3 
 Coefficient# 
(95%CI) 
p Coefficient# 
(95%CI) 
p 
     
Slope to delivery  -0.046 (-0.06, -0.03) <0.0001 -0.047 (-0.06, -
0.03) 
<0.0001 
Modified HAART regimen 
in pregnancy 
  -  
 No 0.00  -  
 Yes 0.27 (-0.09, 0.63) 0.14 -  
Race by IDU     
 White non-IDU 0.00    
 Black non-IDU 0.29 (-0.09, 0.67) 0.14 0.49 (0.02, 0.95) 0.04 
 White IDU -0.21 (-0.65, 0.23) 0.34 -0.09 (-0.62, 0.42) 0.71 
Type of HAART regimen at 
conception 
    
 PI-containing 0.00  0.00  
 NNRTI-containing -0.41 (-0.76, -0.06) 0.02 -0.48 (-0.88, -0.07) 0.02 
Duration of HAART at 
conception 
    
 ≥ 15 months 0.00  0.00  
 6-15 months 0.08 (-0.36, 0.52) 0.72 0.12 (-0.39, 0.64) 0.63 
 < 6 months 0.16 (-0.22, 0.54) 0.40 0.29 (-0.18, 0.76) 0.22 
Baseline CD4 count 
(cells/mm3) 
    
 ≥ 500 0.00  0.00  
 200-499 0.072 (-0.31, 0.46) 0.72 -0.02 (-0.44, 0.41),  0.94 
 <200 0.52 (0.014, 1.03) 0.04 0.78 (0.16, 1.41) 0.01 
#Adjusted for by time period and type of assay used 
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Figure 1. Scatterplot of HIV RNA measurements over pregnancy, with a 
supersmoother to summarize the trend  
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